15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 21 firms covering Intellia Therapeutics Inc, 11 rate it Buy or better, 7 sit at Hold, and 3 rate it Sell or worse, a hold consensus. The target range is very wide, $8.00 to $49.00 (about 6.1x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $19.88 sits 83% above the current $10.89. Sentiment has cooled somewhat, with Sell ratings rising from 2 to 3 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.78 next quarter toward $-1.76 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS21 ratings
Hold
Strong Buy00%
Buy1152%
Hold733%
Sell314%
Strong Sell00%
Based on 21 analysts giving stock ratings to Intellia Therapeutics Inc.
As of Jul, 11 of 21 firms rate NTLA a Buy (7 Hold, 3 Sell), the standing distribution of every covering firm's most recent active call.
NTLA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.78
Range $-0.96 – $-0.64 · 16 analysts · -15% YoY
Next period, 16 analysts expect Intellia Therapeutics Inc to earn $-0.78 a share (range $-0.96 – $-0.64), versus $-0.92 a year earlier. Full-year consensus is $-3.14, growing to $-1.76 the year after.
REVENUE · NEXT QUARTER
$13.0M
Range $0 – $16.6M · 16 analysts · -5% YoY
Revenue is expected to reach $13.0M (range $0 – $16.6M), -5.4% year-over-year. Full-year consensus is $59.2M, rising to $268.4M next year.
Top analysts covering Intellia Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NTLA.
#1
Silvan Tuerkcan
JMP Securities · Rank #29
Buy
$30.00+175.5% to target
Overall win rate
50%
+ Follow
#2
Geulah Livshits
Chardan Capital · Rank #100
Buy
$30.00+175.5% to target
Overall win rate
44%
+ Follow
#3
David Nierengarten
Wedbush · Rank #115
Hold
$17.00+56.1% to target
Overall win rate
41%
+ Follow
#4
Mitchell Kapoor
HC Wainwright & Co. · Rank #165
Buy
$25.00+129.6% to target
Overall win rate
34%
+ Follow
#5
Jay Olson
Oppenheimer · Rank #302
Buy
$27.00+147.9% to target
Overall win rate
32%
+ Follow
NTLA stock forecast FAQ
What is NTLA's average 12-month price target?+
The 17 analysts with a live target average $19.88 for Intellia Therapeutics Inc over the next 12 months, ranging from a $49.00 high to a $8.00 low.
Is NTLA stock a Buy, Sell or Hold right now?+
The current consensus is Hold. Of the 21 analyst ratings, 11 are Buy or Strong Buy, 7 are Hold, and 3 are Sell or Strong Sell.
What are the highest and lowest price targets for NTLA?+
The Street-high target is $49.00 (Canaccord Genuity), and the Street-low is $8.00 (Evercore ISI Group). The average of all 17 active targets is $19.88.
How many Wall Street analysts cover NTLA?+
21 analysts have an active rating on Intellia Therapeutics Inc, and 17 firms carry a live 12-month price target.
Who is the most accurate analyst covering NTLA?+
Among analysts who currently cover NTLA, Silvan Tuerkcan of JMP Securities has the strongest overall Quantellect track record (Rank #29). Their current call is Buy with a $30.00 target.
What is Intellia Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.78 per share (range $-0.96 – $-0.64) across 16 analysts. Full-year EPS is projected at $-3.14, rising to $-1.76 the following year.
How much revenue is Intellia Therapeutics Inc expected to report next quarter?+
Consensus revenue is $13.0M (range $0 – $16.6M). Full-year revenue is projected at $59.2M, growing to $268.4M next year.
Have analysts been upgrading or downgrading NTLA lately?+
As of Jul, 11 of 21 firms rate NTLA a Buy (7 Hold, 3 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NTLA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
